- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02466477
Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder
A Three-arm, Parallel Group, Multicentre, Double-blind, Randomized Controlled Trial Evaluating the Impact of GeneSight Psychotropic and Enhanced-GeneSight Psychotropic, on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic
Study Overview
Status
Detailed Description
The primary objectives of this study are 1) to compare the efficacy of GEN to treatment as usual (TAU) in improving response to psychotropic treatment in outpatients suffering from a MDD and having had - within the current episode - an inadequate response to at least one psychotropic medication included in GEN; and 2) to validate the utility of the new CAMH markers and demonstrate the superior predictive capabilities and greater clinical utility of E-GEN as compared to GEN.
This study is designed as a three-arm multi-centre, double-blind (participants and raters), randomized controlled trial to compare the clinical and economic outcomes of GEN, E-GEN and TAU for patients suffering from a MDD and having had - within the current episode - an inadequate response to at least one psychotropic medication included in GEN. Participants will be randomized in a 1:1:1 ratio to each of the three treatment arms. Recruitment will be 24 months. Follow-up will be 12 months.
Subjects will complete short diagnostic interviews specific to their clinical diagnosis, basic metabolic measures (eg. blood pressure, weight), and provide buccal swab samples for genetic analysis (the unanalyzed buccal swabs and associated DNA will be biobanked). During the first visit, blood and urine samples will be required for laboratory panel screening and blood biobanking. Subjects will be monitored over a one year period and clinical measures and healthcare resource utilization will be obtained. Treating clinicians in the GEN and E-GEN arms will receive an easy to implement report providing pharmacogenomic guidance for prescribing psychotropic medications to their patients.
The study will recruit subjects from 10 sites, stratified into 2 clusters. Nine study sites altogether will form one of the two stratified clusters. CAMH will constitute the tenth study site and the second stratified cluster.The sample size required for this study was calculated using effect size estimates drawn from a previous study conducted by Hall-Flavin et al [Pharmacogenetics Genomics 2013; 23(10)]. Assuming an effect size of 0.30 in HAM-D17 score favoring the treatment group, intra class coefficient between clusters of 20%, statistical power of 90%, an alpha level of 0.05, and an expected 16.7% rate of premature discontinuation by Week 8 (primary endpoint), a total of 570 subjects (i.e., 190 per treatment arm) are required to detect the same effect in this study.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Ontario
-
Chatham, Ontario, Canada, N7L 1B7
- Chatham-Kent Clinical Trials Research Center
-
Hamilton, Ontario, Canada, L8M 1K7
- Hamilton Medical Research Group
-
Hamilton, Ontario, Canada, L8L 5G8
- Hamilton Community Health Centre Family Health Organization
-
Hamilton, Ontario, Canada, L8N 3K7
- St. Joseph's Healthcare Hamilton (SJHH)
-
London, Ontario, Canada, N6A 5W9
- London Health Sciences Centre
-
London, Ontario, Canada, N5W6A2
- Milestone Research
-
London, Ontario, Canada, N6C 0A7
- Parkwood Institute, London
-
Ottawa, Ontario, Canada, K1K0T2
- Hopital Montfort
-
Thornhill, Ontario, Canada, L4J 1E9
- Thornhill Medical Centre
-
Toronto, Ontario, Canada, M5S 1B2
- Women's College Hospital
-
Toronto, Ontario, Canada, M3J 2C5
- Canadian Phase Onward Inc.
-
Toronto, Ontario, Canada, M5T 3L9
- Sinai Health System
-
Toronto, Ontario, Canada, M9W 4L6
- Manna Research
-
Toronto, Ontario, Canada, M6J 1H4
- Centre for Addiction and Mental Health (CAMH)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years of age or older;
- Suffer from a Major Depressive Episode meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria;
- Have had an inadequate response within the current episode to at least one psychotropic treatment in GEN. Inadequate response is defined as inadequate efficacy after 6 weeks of a psychotropic treatment or discontinuation of a psychotropic treatment due to adverse events (AEs) or intolerability;
- Have each a score on the 16-item Clinician Quick Inventory of Depressive Symptomatology (QIDS-C16) and 16-item Self-Report Quick Inventory of Depressive Symptomatology (QIDS-SR16) rating scales ≥ 11;
- Be able to understand the requirements of the study and provide written informed consent to participate in this study;
- Agree to abide by the study protocol and its restrictions and be able to complete all aspects of the study, including all visits and tests.
Exclusion Criteria:
- Patients posing a serious suicidal risk and/or in need of immediate hospitalization as judged by the Investigator;
- Patients with a diagnosis of Bipolar I or II disorder;
Patients with a current Axis I diagnosis of:
- Delirium
- Dementia
- Amnestic and/or other cognitive disorder
- Schizophrenia or other psychotic disorder;
- Patients having experienced hallucinations, delusions, or any psychotic symptomatology within the current depressive episode or during prior depressive episodes;
- Patient is currently in an inpatient facility;
- Patients with a history of hypothyroidism unless taking a stable dose of thyroid medication and asymptomatic or euthyroid for at least 6 months;
- Patients who meet DSM-IV-TR criteria for any significant current substance use disorder;
Patients with:
- hepatic insufficiency (three times the upper limit of normal (ULN) for aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)); liver transplant recipient; cirrhosis of the liver;
- malignancy (except basal cell carcinoma) and/or chemotherapy within 1 year prior to screening; malignancy more than 1 year prior to screening must have been local and without metastasis and/or recurrence, and if treated with chemotherapy, without nervous system complications;
- significant unstable medical condition or life threatening disease with - need for therapies that may obscure the results of treatment and/or of the study;
- Participation in another clinical trial within 30 days of the screening visit;
- Anticipated inability to attend scheduled study visits;
- Patients who in the judgment of the Investigator may be unreliable or uncooperative with the evaluation procedure outlined in this protocol;
- Patients with a history of prior pharmacogenomic testing;
- Any change in psychotropic medication (including change in dosage) between screening and baseline;
- Patients currently receiving electroconvulsive therapy (ECT), deep brain stimulation (DBS) or transcranial magnetic stimulation (TMS) treatments, or currently scheduled to receive maintenance treatments of ECT, DBS, or TMS during the course of the study;
- Patients who self-report to be pregnant or lactating;
- Patients with a history of gastric bypass surgery.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: GeneSight Psychotropic (GEN)
The GeneSight Psychotropic (GEN) product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection.
More specifically, patients are tested for clinically important genetic variants of multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to metabolize, tolerate or respond to medications.
|
Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm.
This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
|
EXPERIMENTAL: Enhanced-GeneSight Psychotropic (E-GEN)
The current GEN test lacks predictive genes for antipsychotic-induced weight gain (AIWG), a major complication of antipsychotic drug use.
Therefore, the Enhanced-GeneSight Psychotropic (E-GEN), which is an enhanced version of the GEN test, was developed by incorporating 6 new genes (represented by 7 SNPs) that are predictive for AIWG, to those used in the GEN algorithm.
An increasing risk level associated with AIWG is estimated by an increasing number of risk genotypes that a given patient possesses among the 7 SNPs.
|
The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG).
The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
|
ACTIVE_COMPARATOR: Treatment as Usual (TAU)
The comparator chosen for this study provides a "real world" comparison of standard of care for patients who receive no pharmacogenomics guidance. Patients randomized to the TAU arm will also have their DNA collected and a pharmacogenomic-based interpretive report will be generated using GEN testing. However, this report will not be shared with the treating clinicians until completion at 12 months of the study. Therefore, patients in this arm will receive clinical treatment as usual, without the use or knowledge of genotyping results by their treating clinicians. |
Subjects randomized to the TAU arm will also require collection of patient DNA.
A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in depressive symptoms as assessed by the 17-item Hamilton Depression (HAM-D17) score
Time Frame: From baseline to Week 8
|
Mean change in the 17-item Hamilton Depression (HAM-D17) score from baseline to Week 8 of the study
|
From baseline to Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes to initial prescribing based on availability of pharmacogenomic data
Time Frame: Screening and Baseline
|
Screening and Baseline
|
|
Change in depressive symptoms as assessed by the 16-Item Clinician Quick Inventory of Depressive Symptomatology (QIDS-SR16)
Time Frame: Baseline, Weeks 8 and 12, and Month 12
|
Baseline, Weeks 8 and 12, and Month 12
|
|
Change in depressive symptoms as assessed by the 9-Item Patient Health Questionnaire (PHQ-9)
Time Frame: Baseline, Weeks 8 and 12, and Month 12
|
Baseline, Weeks 8 and 12, and Month 12
|
|
Change in anxiety symptoms as assessed by theGeneralized Anxiety Disorder 7-Item (GAD-7) Scale
Time Frame: Baseline, Weeks 8 and 12, and Month 12
|
Baseline, Weeks 8 and 12, and Month 12
|
|
Change in severity of illness as assessed by the Clinical Global Impression of Severity (CGI-S)
Time Frame: Baseline, Week 12 and Month 12
|
Baseline, Week 12 and Month 12
|
|
Change in global improvement as assessed by the Clinical Global Impression of Improvement (CGI-I)
Time Frame: Week 12, and Month 12
|
Week 12, and Month 12
|
|
Change in global therapeutic benefit and global severity of side effects as assessed by the Clinical Global Impression Efficacy Index
Time Frame: Week 12 and Month 12
|
Week 12 and Month 12
|
|
Response rates to psychotropic medication
Time Frame: Baseline, Weeks 8 and 12, Months 6, 9 and 12
|
A responder is defined as a participant with 50% decrease in HAM-D17 score from baseline.
|
Baseline, Weeks 8 and 12, Months 6, 9 and 12
|
Remission rates
Time Frame: Baseline, Weeks 8 and 12, Months 6, 9 and 12
|
A remitter is defined as a participant with HAM-D17 score equal or less that 7.
|
Baseline, Weeks 8 and 12, Months 6, 9 and 12
|
Time to response
Time Frame: Baseline, Weeks 8 and 12, Months 6, 9 and 12
|
Baseline, Weeks 8 and 12, Months 6, 9 and 12
|
|
Time to remission
Time Frame: Baseline, Weeks 8 and 12, Months 6, 9 and 12
|
Baseline, Weeks 8 and 12, Months 6, 9 and 12
|
|
Change in psychotropic medication side effects as assessed by the Udvalg for Kliniske Undersogeler (UKU) Side Effect Rating Scale
Time Frame: Baseline, Weeks 8 and 12, and Month 12
|
Baseline, Weeks 8 and 12, and Month 12
|
|
Change in global measure of side effects (frequency, intensity, and burden domains) as assessed by the Frequency, Intensity, and Burden of Side Effects Ratings (FIBSER)
Time Frame: Baseline, Weeks 8 and 12, and Month 12
|
Baseline, Weeks 8 and 12, and Month 12
|
|
Weight gain
Time Frame: Baseline, Weeks 8 and 12, and Month 12
|
Subject's weight
|
Baseline, Weeks 8 and 12, and Month 12
|
Waist-to-hip ratio
Time Frame: Baseline, Weeks 8 and 12, and Month 12
|
Subject's waist and hip measurements
|
Baseline, Weeks 8 and 12, and Month 12
|
Change in health related quality of life as assessed by the EuroQol (EQ-5D-5L)
Time Frame: Baseline, Week 12, Months 6, 9 and 12
|
Baseline, Week 12, Months 6, 9 and 12
|
|
Change in health related quality of life as assessed by the Short Form (36) Health Survey (SF-36)
Time Frame: Baseline, Week 12, Months 6, 9 and 12
|
Baseline, Week 12, Months 6, 9 and 12
|
|
Pharmacogenetics in Psychiatry Follow-up Questionnaire (PIPFQ)
Time Frame: Baseline, when prescription changes are made (expected average of every 4 weeks), and Month 12
|
The PIPFQ is a questionnaire developed by CAMH to evaluate each physician's attitude and experience to pharmacogenomic testing.
Information is solicited from the physician on three different domains: the processing of the physician's last referral, the contact and outcome of the physician's patient, and the physician's perspective on the future of genetic studies in psychiatric drug treatment.
|
Baseline, when prescription changes are made (expected average of every 4 weeks), and Month 12
|
Healthcare resource utilization (Composite measure of healthcare costs): physician visits, hospital utilization, emergency department visits, medication use, and laboratory tests
Time Frame: Baseline, Weeks 8 and 12, Months 6, 9 and 12
|
Baseline, Weeks 8 and 12, Months 6, 9 and 12
|
|
Productivity losses (measured as economic costs)
Time Frame: Baseline, Weeks 8 and 12, Months 6, 9 and 12
|
Baseline, Weeks 8 and 12, Months 6, 9 and 12
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EXCITE-013304-ARX1009.PTL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedDepressive Disorder, Major Depressive DisorderUnited States
-
Samsung Medical CenterUnknownMajor Depressive Disorder, Anxiety DisorderKorea, Republic of
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
Clinical Trials on GeneSight Psychotropic (GEN)
-
St. Joseph's Healthcare HamiltonCentre for Addiction and Mental Health; Assurex Health Inc.; Genome Canada; Programs... and other collaboratorsCompletedSchizophrenia | Schizoaffective DisorderCanada
-
Assurex Health Inc.University of MichiganCompletedMajor Depressive Disorder (MDD)United States
-
Mayo ClinicAssurex Health HomeCompletedDepressionUnited States
-
Washington University School of MedicineAssureRx Health, Inc.TerminatedDepressive Disorder | Depression | Major Depressive Disorder | Depression, Unipolar | Depressive EpisodeUnited States
-
Claret MedicalMeditrial Europe Ltd.Completed
-
Massachusetts General HospitalPatient-Centered Outcomes Research Institute; Duke University; Montefiore Medical... and other collaboratorsCompletedMajor Depressive DisorderUnited States
-
Seno Medical Instruments Inc.SuspendedBreast CancerUnited States
-
Genocea Biosciences, Inc.CompletedStreptococcus PneumoniaeUnited States
-
Abbott Medical DevicesCompletedCarotid Artery DiseaseUnited States
-
Mayo ClinicCompleted